BOSCO, Raffaella
 Distribuzione geografica
Continente #
NA - Nord America 751
EU - Europa 149
AS - Asia 143
OC - Oceania 1
Totale 1.044
Nazione #
US - Stati Uniti d'America 750
CN - Cina 85
UA - Ucraina 38
SG - Singapore 34
DE - Germania 30
IT - Italia 29
GB - Regno Unito 25
TR - Turchia 22
FI - Finlandia 9
SE - Svezia 7
BE - Belgio 4
FR - Francia 2
LT - Lituania 2
NL - Olanda 2
AU - Australia 1
CA - Canada 1
CZ - Repubblica Ceca 1
IN - India 1
JP - Giappone 1
Totale 1.044
Città #
Fairfield 124
Woodbridge 96
Ashburn 65
Houston 59
Chandler 52
Seattle 51
Jacksonville 46
Cambridge 45
Wilmington 33
Singapore 32
Beijing 27
New York 20
Santa Clara 20
Izmir 17
Ferrara 13
San Diego 13
Nanjing 12
Ann Arbor 11
Princeton 9
Boardman 8
Shanghai 8
Milan 6
Shenyang 5
Bremen 4
Brussels 4
Washington 4
Changsha 3
Haikou 3
Munich 3
Auburn Hills 2
Bologna 2
Jiaxing 2
Leawood 2
Los Angeles 2
Nanchang 2
Ningbo 2
Orange 2
Padova 2
Tianjin 2
West Lafayette 2
Augusta 1
Dearborn 1
Frankfurt am Main 1
Guiyang 1
Hangzhou 1
Hebei 1
Jinan 1
Kunming 1
Lanzhou 1
Linköping 1
Mountain View 1
Norwalk 1
Olomouc 1
Redwood City 1
San Mateo 1
Taiyuan 1
Taizhou 1
Tappahannock 1
Torino 1
Toronto 1
Verona 1
Weiden 1
Zhengzhou 1
Totale 838
Nome #
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts 134
Molecular targets for selective killing of TRAIL-resistant leukemic cells. 118
Anti-leukemic activity of Dasatinib in both p53(wild-type) and p53 (mutated) B malignant cells. 118
null 97
null 94
null 92
null 90
null 83
null 76
Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. 32
miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. 30
Dasatinib plus Nutlin-3 shows synergistic anti-leukemic activity in both p53wild-type and p53mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. 29
Baseline serum concentrations of TRAIL in early rheumatoid arthritis: Relationship with response to disease-modifying antirheumatic drugs 25
Nutlin-3 downregulates the expression of the Oncogene TCL1 in primary B Chronic Lymphocytic Leukemic cells. 20
Recent advances in the therapeutic perspectives of Nutlin-3 20
Totale 1.058
Categoria #
all - tutte 4.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.224


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020164 0 0 0 0 18 26 21 28 21 33 14 3
2020/2021139 12 13 2 24 15 11 6 15 3 14 18 6
2021/2022118 2 11 25 3 4 4 8 6 4 6 18 27
2022/2023112 11 12 3 14 17 17 4 5 13 4 8 4
2023/202453 1 7 0 0 0 23 4 1 1 1 2 13
2024/202584 5 2 19 20 38 0 0 0 0 0 0 0
Totale 1.058